MedTrace Logo

Malignant Ascites Alfapump® Study

NCT04076566 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2020-08-10

No results posted yet for this study

Summary

ProMAS is a prospective post-marketing, single-arm study to assess performance and safety of the Alfapump® system in the treatment of patients with malignant ascites. The study aims to enroll 40 patients in up to 8 sites in Europe.

Conditions

  • Malignant Ascites

Interventions

DEVICE

alfapump system

active implantable device for treatment of malignant ascites

Sponsors & Collaborators

  • Sequana Medical N.V.

    lead INDUSTRY

Principal Investigators

  • Christina Fotopoulou, Prof, MD · Imperial Hospital, London, UK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-31
Primary Completion
2021-12-31
Completion
2022-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04076566 on ClinicalTrials.gov